These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 32977825)
1. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825 [TBL] [Abstract][Full Text] [Related]
2. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses. Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700 [TBL] [Abstract][Full Text] [Related]
3. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction. Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557 [TBL] [Abstract][Full Text] [Related]
4. Case series of equine pituitary pars intermedia dysfunction in a tropical climate. Spelta CW; Axon JE Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327 [TBL] [Abstract][Full Text] [Related]
5. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757 [TBL] [Abstract][Full Text] [Related]
6. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction. Gehlen H; Fisch J; Merle R; Trachsel DS J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515 [TBL] [Abstract][Full Text] [Related]
7. Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction. Huang L; Palmieri C; Bertin FR Res Vet Sci; 2022 Dec; 152():427-433. PubMed ID: 36126509 [TBL] [Abstract][Full Text] [Related]
8. Equine pituitary pars intermedia dysfunction. McFarlane D Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656 [TBL] [Abstract][Full Text] [Related]
9. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses. Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. Rendle DI; Doran G; Ireland J; Edwards S Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785 [TBL] [Abstract][Full Text] [Related]
12. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses. Rendle DI; Duz M; Beech J; Parkin T; Durham AE J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review. Tatum RC; McGowan CM; Ireland JL Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. McFarlane D; Banse H; Knych HK; Maxwell LK J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465 [TBL] [Abstract][Full Text] [Related]
15. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy. Banse HE; Whitehead AE; McFarlane D; Chelikani PK Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552 [TBL] [Abstract][Full Text] [Related]
16. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction. Pease AP; Schott HC; Howey EB; Patterson JS J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144 [TBL] [Abstract][Full Text] [Related]
17. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group. Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508 [TBL] [Abstract][Full Text] [Related]
18. Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction. Hague N; Durham AE; Menzies-Gow NJ Vet Rec; 2021 Jul; 189(1):e142. PubMed ID: 33759215 [TBL] [Abstract][Full Text] [Related]
19. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571 [TBL] [Abstract][Full Text] [Related]
20. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. McFarlane D; Holbrook TC J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]